GlassScriptPhysician profile
Tamneet Basra
NPI 1467806778
$4,268.52
in general payments reported to CMS, 2019-2025
26 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $227 · 2022: $110 · 2023: $1,040 · 2024: $1,619 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,931.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $918.23 | 2020-2025 | Avycaz, Mavyret, Teflaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $900.46 | 2023-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $507.52 | 2022-2025 | |
| Madrigal Pharmaceuticals | $298.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Eisai INC. | $234.78 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $172.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $157.31 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $148.19 | 2024-2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $121.16 | 2022-2025 | Livtencity |
| Merck Sharp & Dohme LLC | $101.77 | 2023-2024 | Keytruda, Zerbaxa, Dificid |
| Incyte Corporation | $100.58 | 2023-2024 | Pemazyre |
| Novo Nordisk INC | $77.61 | 2023-2025 | Wegovy |
| Orphalan INC | $64.80 | 2024-2025 | Cuvrior |
| Smith+Nephew, INC. | $63.66 | 2023-2024 | Stravix Pl, Oasis |
| Mallinckrodt Hospital Products INC. | $56.01 | 2025 | Terlivaz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $54.29 | 2024 | Balfaxar |
| Boston Scientific Corporation | $44.85 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Dynavax Technologies Corporation | $39.46 | 2022-2024 | Heplisav-B |
| Alexion Pharmaceuticals, INC. | $33.28 | 2024 | Ultomiris |
| Caris Mpi, INC. | $31.10 | 2025 | Mi Cancer Seek |
| La Jolla Pharmaceutical Company | $30.29 | 2025 | Giapreza |
| Genentech USA, INC. | $26.61 | 2025 | Tecentriq |
| Albireo Pharma, INC. | $24.57 | 2024 | Iqirvo |
| Kerecis Limited | $22.01 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Lilly USA, LLC | $21.82 | 2025 | Zepbound |
| Melinta Therapeutics, LLC | $16.93 | 2024 | Rezzayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamneet Basra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.